TABLE 1.
BG assay results (and efficiency parameters) for the diagnosis of IFI in patients, in populations at risk for IFI, and in subgroups at risk for IPA and/or bloodstream infection
| Parametera | IFI patient groups and subgroups/control groups
|
|||
|---|---|---|---|---|
| Total IFI patients/ blood donors | Total IFI patients/ patients at risk | Pulmonary aspergillosis/corresponding patients at risk | Bloodstream infections/corresponding patients at risk | |
| No. of patients | 117/40 | 117/122 | 70/100 | 27/101 |
| No. of patients with a BG ≥80 pg/ml | 91/3 | 91/36 | 48/27 | 23/36 |
| Sensitivity (95% CI) | 77.8 (70.2-85.3) | 77.8 (70.2-85.3) | 68.6 (57.7-79.5) | 85.2 (71.8-98.6) |
| Specificity (95% CI) | 92.5 (84.3-1.0) | 70.5 (62.4-78.6) | 73.0 (64.3-81.7) | 64.4 (55.0-73.7) |
| LR+ (95% CI) | 10.4 (3.5-30.9) | 2.64 (1.97-3.53) | 2.54 (1.77-3.64) | 2.39 (1.76-3.24) |
| LR− (95% CI) | 0.24 (0.17-0.34) | 0.32 (0.22-0.45) | 0.43 (0.30-0.62) | 0.23 (0.09-0.57) |
| Yule Q | 0.95 | 0.79 | 0.71 | 0.82 |
a
LR, likelihood ratio. The Yule Q coefficient measures the strength of the association between the test results and the disease (0, null; 0.01 to 0.09, negligible; 0.10 to 0.29, light; 0.30 to 0.49, moderate; 0.50 to 0.69, strong; 0.70 to 1, very strong).